Simplicity Wealth LLC Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Simplicity Wealth LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,306 shares of the biopharmaceutical company’s stock, valued at approximately $483,000.

Several other institutional investors have also modified their holdings of GILD. GAMMA Investing LLC raised its position in Gilead Sciences by 24.9% during the first quarter. GAMMA Investing LLC now owns 22,760 shares of the biopharmaceutical company’s stock valued at $2,550,000 after buying an additional 4,532 shares during the period. Octavia Wealth Advisors LLC acquired a new position in Gilead Sciences during the first quarter valued at $211,000. Investment Advisory Group LLC acquired a new position in Gilead Sciences during the first quarter valued at $218,000. Tounjian Advisory Partners LLC acquired a new position in Gilead Sciences during the first quarter valued at $424,000. Finally, Farther Finance Advisors LLC raised its position in Gilead Sciences by 94.3% during the first quarter. Farther Finance Advisors LLC now owns 37,487 shares of the biopharmaceutical company’s stock valued at $4,172,000 after buying an additional 18,194 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $110.42, for a total value of $1,104,200.00. Following the transaction, the chief executive officer now owns 620,268 shares of the company’s stock, valued at approximately $68,489,992.56. This trade represents a 1.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the transaction, the insider now directly owns 121,152 shares in the company, valued at approximately $13,026,263.04. The trade was a 18.77% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 43,000 shares of company stock valued at $4,630,310 in the last 90 days. 0.27% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on GILD shares. JPMorgan Chase & Co. upped their target price on Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a research report on Thursday, March 27th. Piper Sandler upped their target price on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Cantor Fitzgerald started coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 target price on the stock. BMO Capital Markets upped their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Finally, The Goldman Sachs Group upped their target price on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.55.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $109.30 on Thursday. The company has a market capitalization of $135.96 billion, a price-to-earnings ratio of 295.41, a PEG ratio of 0.71 and a beta of 0.29. Gilead Sciences, Inc. has a twelve month low of $62.69 and a twelve month high of $119.96. The stock has a fifty day simple moving average of $105.40 and a 200 day simple moving average of $101.91. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period last year, the business posted ($1.32) EPS. The business’s revenue was down .3% compared to the same quarter last year. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.89%. Gilead Sciences’s dividend payout ratio (DPR) is presently 66.53%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.